Guilford Pharmaceuticals Inc. on Thursday said adjustments in its voluntarily suspended Phase III study with Aquavan may extend only "modestly" the time to filing a new drug application, but Wall Street proved unforgiving, as investors took away more than 33 percent of the stock's value. (BioWorld Today)